<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516551</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-CD19 allo-CAR-T</org_study_id>
    <nct_id>NCT04516551</nct_id>
  </id_info>
  <brief_title>Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT</brief_title>
  <official_title>Anti-CD19 Donor-derived CAR-T Cells for Patients With Relapsed B Cell Malignancies After Hematopoietic Stem Cell Transplantation: a Multi-center, Uncontrolled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Shanghai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital Of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The General Hospital of Western Theater Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem&#xD;
      cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time&#xD;
      after transplantation. Nowadays there is no effective way to salvage patients in such&#xD;
      conditions. T cells derived from healthy matched sibling or unrelated donors have not been&#xD;
      restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve&#xD;
      well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved&#xD;
      the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The stunning response rate of anti-CD19(cluster of differentiation antigen 19)&#xD;
      auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or&#xD;
      refractory B-cell hematologic malignancies. However, for B-ALL patients suffered from relapse&#xD;
      after allo-HSCT (hematopoietic stem cell transplant), the T cells derived from healthy donor&#xD;
      seems like a better origin for CAR-T cells producing because T cells derived from healthy&#xD;
      matched sibling or unrelated donors have not been restrained by tumor micro-environment and&#xD;
      retain anti-leukemia ability. So after we designed a clinical trial to manifest the safety&#xD;
      and efficacy of anti-CD19 CAR-T cells for patients with relapsed B cell ALL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the safety of anti-CD19 allo CAR-T cells</measure>
    <time_frame>within 4 weeks after infusion</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the efficacy of anti-CD19 allo CAR-T cells</measure>
    <time_frame>4 weeks after infusion</time_frame>
    <description>ratio of bone marrow blast cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The long-term efficiency</measure>
    <time_frame>up to 2 years after infusion</time_frame>
    <description>ratio of bone marrow blast cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Relapsed Adult ALL</condition>
  <condition>B Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>anti-CD19 allo-CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the &quot;3 + 3&quot; dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.&#xD;
dosage: the number of anti CD19+CD22 CAR T cells&#xD;
-1(if needed) 1×10^6/KG&#xD;
3×10^6 /KG 6×10^6 /KG 1×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19 allo-CAR-T cells</intervention_name>
    <description>The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.</description>
    <arm_group_label>anti-CD19 allo-CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of relapsed B-cell acute lymphoblastic leukemia (B-ALL).&#xD;
&#xD;
          2. Patients have received hematologic stem cell transplantation from matching sibling&#xD;
             donor or unrelated donor.&#xD;
&#xD;
          3. CD19-positive tumor (&gt;20% CD19 positive blasts by flow cytometry or&#xD;
             immunohistochemistry (tissue)）&#xD;
&#xD;
          4. Hgb ≥ 7.0 (can be transfused)&#xD;
&#xD;
          5. Life expectancy greater than 12 weeks&#xD;
&#xD;
          6. Informed consent explained to, understood by and signed by the patient/guardian. The&#xD;
             patient/guardian is given a copy of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other tumors except cured non-melanoma skin cancer, cervical cancer in situ,&#xD;
             superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with&#xD;
             complete remission of more than 5 years)；&#xD;
&#xD;
          2. Severe mental disorders；&#xD;
&#xD;
          3. A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman&#xD;
             syndrome, or any other known bone marrow failure syndrome；&#xD;
&#xD;
          4. Subjects with II-IV grade acute graft versus host disease GVHD (Glucksberg Standrad)&#xD;
             or chronic GVHD.&#xD;
&#xD;
          5. Heart disease with grade III-IV heart failure [NYHA classification], myocardial&#xD;
             infarction, angioplasty or stenting, unstable angina or other heart diseases with&#xD;
             prominent clinical symptoms within one year before admission；&#xD;
&#xD;
          6. Subjects with any indwelling catheter or drainage tube (such as percutaneous&#xD;
             nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter),&#xD;
             should be excluded. (Special central venous catheter is allowed)；&#xD;
&#xD;
          7. Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis；&#xD;
&#xD;
          8. Subjects with a history of CNS disease,such as epilepsy, cerebral ischemia/hemorrhage,&#xD;
             dementia, cerebellar disease, or any autoimmune disease involving CNS；&#xD;
&#xD;
          9. Any of the following virological ELISA results are positive: HIV antibody, HCV&#xD;
             antibody, TPPA, HBsAg；&#xD;
&#xD;
         10. Active infection requiring systematic treatment within 2 weeks before single&#xD;
             collection；&#xD;
&#xD;
         11. Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or&#xD;
             diagnosed as the allergy；&#xD;
&#xD;
         12. History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic&#xD;
             lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive&#xD;
             medications or systemic disease modifying drugs in the past 2 years；&#xD;
&#xD;
         13. Presence of pulmonary fibrosis；&#xD;
&#xD;
         14. Subjects who have received other clinical trial treatment within 4 weeks before&#xD;
             participating in this trial should be excluded. Or the signing date of informed&#xD;
             consent is within 5 half-lives of the last application of another clinical trial&#xD;
             (whichever is longer)；&#xD;
&#xD;
         15. Subjects with poor compliance due to physiological, family, social, geographical and&#xD;
             other factors, or those unable to cooperate with the study plan or follow-up；&#xD;
&#xD;
         16. At the discretion of the investigator, there are complications requiring systemic&#xD;
             corticosteroid therapy (≥ 5mg / day of prednisone or equivalent dose of other&#xD;
             corticosteroids) or other immunosuppressive drugs within 6 months after this clinical&#xD;
             research treatment；&#xD;
&#xD;
         17. The lactating woman who is reluctant to stop breastfeeding；&#xD;
&#xD;
         18. Any other condition considered unsuitable by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Zhang, MD phD</last_name>
    <role>Study Chair</role>
    <affiliation>Xinqiao Hospital of Chongqing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>He Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Zhang, MD phD</last_name>
    <phone>13808310064</phone>
    <phone_ext>+86</phone_ext>
    <email>zhangxxi@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruihao Huang</last_name>
    <phone>18984398751</phone>
    <phone_ext>+86</phone_ext>
    <email>1169731117@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Xinqiao Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihao Huang</last_name>
      <phone>18984398751</phone>
      <phone_ext>+86</phone_ext>
      <email>1169731117@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Xi Zhang, MD</investigator_full_name>
    <investigator_title>Chef of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

